Vaikunth, LLC inspected by FDA in Houston on June 13, 2024

Hilary Marston, M.D., M.P.H. Chief Medical Officer (CMO) of the FDA - Official Website
Hilary Marston, M.D., M.P.H. Chief Medical Officer (CMO) of the FDA - Official Website
0Comments

The Food and Drug Administration (FDA) carried out an inspection at Vaikunth, LLC located in Houston on June 13, 2024, according to data posted on the FDA’s website.

The FDA’s final report recommended that Vaikunth, LLC address issues related to managing operations concerning foodborne biological hazards. No corrective measures were deemed necessary for other inspected areas.

The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.

According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.

Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.



Related

Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA - Official Website

Bayou City Hemp Company inspected by FDA in Houston on Aug. 19, 2024

On August 19, 2024, the Food and Drug Administration conducted an inspection of Bayou City Hemp Company in Houston focused on foodborne biological hazards, according to FDA records.

Leah Hunter Commissioner for External Affairs (OEA) within the Office of the Commissioner at the U.S. Food and Drug Administration - Official Website

Topway Enterprises, Inc. in Houston inspected by FDA on May 8, 2024

The FDA conducted an inspection at Topway Enterprises, Inc. in Houston on May 8, 2024, focusing on foodborne biological hazards.

Vid Desai FDA’s Chief Information Officer - Official Website

FDA inspects Ghayas Issa, M.D. in Houston on March 14, 2024

The FDA conducted a bioresearch monitoring inspection at Ghayas Issa, M.D. in Houston on March 14, 2024.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from Houston Republic.